Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
Hyrich KL., Silman AJ., Watson KD., Symmons DP.
Anti-TNFalpha therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.